Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
View Patent ↗Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment.
1. A method for administering nitric oxide (NO) to a subject comprising
a) administering a non-porphyrin metal nitrosyl to a tissue of said subject, and
b) illuminating said non-porphyrin metal nitrosyl with light under conditions suitable for causing said non-porphyrin metal nitrosyl to release NO,
wherein said non-porphyrin metal nitrosyl has a formula selected from the group consisting of
wherein
E is N, O or S,
Na is carboxamido-N;
M is a group 7 or group 8 transition metal in a +2, +3 or +4 oxidation state, and is not Fe II .
2. The method of claim 1 , wherein said transition metal is selected from the group consisting of Mn II , and R III .
3. The method of claim 2 , wherein said non-porphyrin metal nitrosyl is an [LM(NO) x ] n+ type, L is said pentadentate ligand, M is said transition metal, x is one or two for number of NO ligands, and n is net charge.
4. The method of claim 2 , wherein said ligand comprises one or more pyridine rings.
5. The method of claim 4 , wherein said ligand is PaPy 3 H.
6. The method of claim 1 , wherein said non-porphyrin metal nitrosyl is [(PaPy 3 )Mn(NO)]ClO 4 .
7. The method of claim 2 , wherein said light comprises ultraviolet light and said low radiant power is in the range of 1 to 50 mWatts.
8. The method of claim 2 , wherein said light comprises visible light and said low radiant power is in the range of 25 to 250 Watts.
9. The method of claim 4 , wherein said ligand is selected from the group consisting of PaPy 2 OH 2 , PaPy 2 SH 2 , PcPy 2 OH 2 , PcPy 2 SH 2 , PcPy 3 H, Me PcPy 3 H, Py 2 PSH, and Me PyPSH 4 .
10. The method of claim 1 , wherein said non-porphyrin metal nitrosyl is [(PaPy 3 )Ru(NO)] (BF 4 ) 2 .
11. The method of claim 1 , wherein said administering is selected from the group consisting of syringe, catheter, transdermal patch, topical, endoscopic, and implantation.
12. The method of claim 1 , wherein said administering comprises a catheter.
13. The method of claim 1 , wherein said illuminating is selected from the group consisting of catheter, endoscope, and fiber-optic.
14. The method of claim 1 , wherein said illuminating comprises a fiber-optic.
15. A method for administering nitric oxide (NO) to a subject comprising
a) administering a non-porphyrin metal nitrosyl to a tissue of said subject, and
b) illuminating said non-porphyrin metal nitrosyl with light under conditions suitable for causing said non-porphyrin metal nitrosyl to release NO,
wherein said non-porphyrin metal nitrosyl has a formula selected from the group consisting of
wherein
E is O or S,
Na is carboxamido-N;
M is a group 7 or group 8 transition metal in a +2, +3 or +4 oxidation state, and is not Fe II .
16. The method of claim 15 , wherein said transition metal is selected from the group consisting of Mn II , and R III .
17. The method of claim 16 , wherein said non porphyrin metal nitrosyl is an [L′M(NO) x ] n− type, L′ is said tetradentate ligand, M is said transition metal, x is one or two for number of NO ligands, and n is net charge.
18. The method of claim 16 , wherein said ligand comprises one or more pyridine rings.
19. The method of claim 4 , wherein said ligand is selected from the group consisting of PaBOH 4 , PaBSH 4 , PcBOH 4 , PcBSH 4 , H 2 bpb, and H 2 Me 2 bqb.
20. The method of claim 1 , wherein said non-porphyrin metal nitrosyl is selected from the group consisting of [(bpb)Ru(NO)(Cl)], [(Me 2 bqb)Ru(NO)(Cl)], [(Me 2 bqb)Ru(NO)(py)], and [(Me 2 bqb)Ru(NO)(Cl)].
21. The method of claim 16 , wherein said light comprises ultraviolet light and said low radiant power is in the range of 1 to 50 mWatts.
22. The method of claim 16 , wherein said light comprises visible light and said low radiant power is in the range of 25 to 250 Watts.
23. The method of claim 15 , wherein said administering is selected from the group consisting of syringe, catheter, transdermal patch, topical, endoscopic, and implantation.
24. The method of claim 15 , wherein said administering comprises a catheter.
25. The method of claim 15 , wherein said illuminating is selected from the group consisting of catheter, endoscope, and fiber-optic.
26. The method of claim 15 , wherein said illuminating comprises a fiber-optic.